SPONSOR
Zhejiang Cancer Hospital
Total Trials
7
Recruiting
7
Phases
Phase 2, Phase 3
Conditions studied: High-risk R/R LBCLPirtobrutinibSintilimabCentral Nervous System LymphomaGastric CancerHealthyIntrahepatic CholangiocarcinomaNasopharyngeal CarcinomaSupraglottic Airway DeviceNon-Resectable Pancreas Carcinoma
Zhejiang Cancer Hospital is a clinical research sponsor with 7 registered studies on ClinicalTrials.gov, of which 7 are actively recruiting participants. Research covers conditions including High-risk R/R LBCL, Pirtobrutinib, Sintilimab, Central Nervous System Lymphoma.
The trial portfolio spans Phase 2, Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Zhejiang Cancer Hospital
How many clinical trials has Zhejiang Cancer Hospital sponsored?
ClinicalMetric currently tracks 7 clinical trials sponsored by Zhejiang Cancer Hospital, of which 7 are actively recruiting participants. These trials cover conditions including High-risk R/R LBCL, Pirtobrutinib, Sintilimab. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Zhejiang Cancer Hospital research focus on?
Zhejiang Cancer Hospital clinical trials span High-risk R/R LBCL, Pirtobrutinib, Sintilimab, Central Nervous System Lymphoma, Gastric Cancer, and additional conditions. The research pipeline includes Phase 2, Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Zhejiang Cancer Hospital clinical trial?
To participate in a Zhejiang Cancer Hospital trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Zhejiang Cancer Hospital trials with current recruitment status updated daily.
Clinical Trials by Zhejiang Cancer Hospital
NCT07538635 Phase 2
Recruiting
CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors.
High-risk R/R LBCL
NCT07416890 Phase 2
Recruiting
Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma
Pirtobrutinib
NCT05991947
Recruiting
Preliminary Experimental Study on Key Technologies for Early Screening of Gastric Cancer
Gastric Cancer
NCT05557578 Phase 2
Recruiting
GOT Applied As Neoadjuvant Regimen for Patients of Resectable ICC with High-risk Factors of Recurrence
Intrahepatic Cholangiocarcinoma
NCT05514275 Phase 2
Recruiting
Radiotherapy Combined With Endostatin and Capecitabine for NPC
Nasopharyngeal Carcinoma
NCT07196696
Recruiting
An in Vivo CT Imaging Study of GMA-Tulip, I-gel, and LMA Supreme (GLAM-II)
Supraglottic Airway Device
NCT07235930 Phase 3
Recruiting
Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer
Non-Resectable Pancreas Carcinoma
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology